The market for Tissue diagnostics is poised to reach $XX million by the end of 2021 growing at a CAGR of XX%. Tissue based diagnostics serves as one of the most important technique for cancer diagnosis. There is no other technology that can capture the disease insights and the parameters that factor into the patient outcomes. Tissue diagnostic aka Histopathology is the study of disease in tissue. Samples usually consist of pieces of tissue in various obtained by various methods. These include small biopsies, large specimens removed at surgery. Tissues generally enable personalized diagnosis & treatment.
Growth of personalized medicine, upsurge of cancer patients, increasing opportunities in digital pathology and high demand for companion & molecular diagnostics are the major factors driving the growth of the market. Limited customer base for tissue diagnostics, limited budget issues and regulatory framework issues are the factors hindering the growth of the market.
The Tissue diagnostic market can be segmented on the basis of By Technology (Immunohistochemistry, In situ hybridization, Digital pathology and workflows, Special staining), By Product (Instruments, Consumables), By Application (Prostrate Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Skin Cancer, Cervical Cancer, Lymphoma, Gastric Cancer), By End User (Hospitals & Clinics, CRO, Research Labs, Pharmaceutical firms) and By Geography.
Tissue tests will spearhead the IVD industry revenue in the future. Currently, North America is the largest market in the world followed by Europe. This can be attributed to the increased awareness about the potential benefits of diagnostics among the population. APAC is the fastest growing segment. The key players for this market are Abbott Laboratories, Roche, Sigma Aldrich, Life Technologies, Danaher Corporation, Agilent Technologies, Biogenex Laboratories, Cell Signalling Technology, 3DHISTECH, Affymetrix, Cancer Genetics,Inc., Definiens, Genomic Health, Inc.
What the report offers